Guatemala Pharmaceuticals and Healthcare Report Q2 2016
BMI View: The commercial incentives for foreign drugmakers to further expand in Guatemala'spharmaceutical market are limited by the country's low per capita pharmaceutical spending and subduedmarket growth. However, in spite of this, the country will continue to attract investment as a regionalpharmaceutical production hub. Since the end of the 36-year civil war in 1996, Guatemala's politicalstability has been progressing and tax incentives are available to encourage foreign investment. The keyrisks to our projection are high levels of bureaucracy, corruption, the complex judicial system and lowsecurity due to non-political violence.Headline Expenditure ProjectionsPharmaceuticals: GTQ6.6bn (USD866mn) in 2015 to GTQ7.1bn (USD917mn) in 2015; +7.1% in localcurrency terms and +5.9% in US dollar terms. Forecast has been reduced from Q116.Healthcare: GTQ30.7bn (USD4.0bn) in 2015 to GTQ32.6bn (USD4.2bn) in 2016; +6.2% in local currencyterms, +5.0% in US dollar terms. Forecast has been reduced from Q116.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook